Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.65 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6382816 | 0.89 | ADRA1A (0.65) | ADRA1ATAAR1 | |
| SCHEMBL27510940 | 0.84 | ABCB1 (0.59) | MTNR1AMTNR1BABCB1HTR1ADRD2 | |
| Ammonia Solution, Strong SCHEMBL27423426 | 0.82 | MTNR1A (0.61) | MTNR1AMTNR1BABCB1HTR1ADRD2 | |
| SCHEMBL25591930 | 0.82 | MTNR1A (0.60) | MTNR1AMTNR1BABCB1HTR1ADRD2 | |
| SCHEMBL30211932 | 0.82 | MTNR1A (0.60) | MTNR1AMTNR1BABCB1HTR1ADRD2 | |
| SCHEMBL13523866 | 0.80 | TRPM8 (0.53) | ADRA1ATAAR1MTNR1A | |
| SCHEMBL479514 | 0.80 | TAAR1 (1.00) | ADRA1ATAAR1 | |
| SCHEMBL29491077 | 0.80 | TAAR1 (1.00) | ADRA1ATAAR1 | |
| SCHEMBL3712815 | 0.79 | MAOB (0.55) | MTNR1AMTNR1BABCB1HTR1ADRD2 | |
| SCHEMBL6260325 | 0.79 | CCR5 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274687-B1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-01-05 | — | — | EP | disclosed |
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-1274687-A1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001068609-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | ADRA1A 110/4885TAAR1 128/4885MTNR1A 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.